<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513639</url>
  </required_header>
  <id_info>
    <org_study_id>OMC01/19</org_study_id>
    <nct_id>NCT04513639</nct_id>
  </id_info>
  <brief_title>The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study</brief_title>
  <official_title>The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Førde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Nord-Trøndelag HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Ostfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after&#xD;
      first line treatment prolongs progression free survival and overall survival for myeloma&#xD;
      patients versus treating relapse after first line treatment at progressive disease. To&#xD;
      establish a homogenous group of MRD negative patients after first line treatment including&#xD;
      autologous stem cell transplantation, patients are enrolled at diagnosis and treated with&#xD;
      Norwegian standard of care first line treatment. MRD negative patients will move on to the&#xD;
      randomized part.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      391 patients with newly diagnosed multiple myeloma eligible for high dose therapy with&#xD;
      autologous stem cell support will be included in the phase II part of the study and receive&#xD;
      standard of care first line treatment according to Norwegian national guidelines; bortezomib-&#xD;
      lenalidomide - dexamethasone for 4 pre-transplant induction and 4 post-transplant&#xD;
      consolidation cycles (all 21-d cycles). After induction patients will undergo tandem or&#xD;
      single ASCT, depending on toxicity and response to first ASCT. The primary endpoint of the&#xD;
      phase 2 part of the study is the number of patients who achieve MRD negative (Euroflow NGF 10&#xD;
      -5 ) complete response 30-45 days post consolidation. Patients (176) achieving MRD negative&#xD;
      complete response will be randomly assigned in a 1:1 ratio to receive second line treatment&#xD;
      at MRD reappearance (arm A) or at progressive disease as defined by the IMWG criteria (arm&#xD;
      B). Randomization will be stratified by R-ISS stage at diagnosis and single vs tandem ASCT.&#xD;
      Patients in arm A will be followed with MRD assessment every 4 month and start second line&#xD;
      treatment at loss of MRD negative CR. Patients in arm B will be followed up by standard&#xD;
      criteria and start second line treatment at progressive disease. Both arms will receive the&#xD;
      same 2.L treatment; carfilzomib - dexamethasone - daratumumab. (all 28-d cycles) Second line&#xD;
      treatment will continue until disease progression, unacceptable AEs or patient withdrawal. In&#xD;
      arm A MRD Euroflow will be assessed after 6 and 18 months of 2L therapy. In arm B MRD&#xD;
      Euroflow will be assessed if &gt;CR is achieved but not before 6 months of 2 L therapy, and&#xD;
      again after 12 consecutive months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2030</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>10 years</time_frame>
    <description>Median PFS of Arm A (MRD guided) vs Arm B (PD guided) defined as the time from randomization to disease progression or death due to any cause following 2.L treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>11 years</time_frame>
    <description>Median OS of Arm A vs Arm B (MRD guided) defined as the time from randomization to death of any cause following 2.L treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal residual disease negativity after first line treatment</measure>
    <time_frame>30-45 days post consolidation</time_frame>
    <description>The number of participants who achieve MRD negativity measured by Euroflow NGF at 30-45 after consolidation therapy has ended</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-next treatment</measure>
    <time_frame>10 years</time_frame>
    <description>Time from end of first line treatment to start of 3.L therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease negativity during second line treatment</measure>
    <time_frame>6 months after starting second line treatment</time_frame>
    <description>The proportion of patients who achieve MRD negativity during 2.L treatment, monitored by MRD Euroflow NGF at 6 and 18 months in arm A and after achieving CR in arm B (first MRD testing after 6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQOL)</measure>
    <time_frame>10 years</time_frame>
    <description>Patient reported outcome HRQOL forms will be filled out by patients at defined time points during the study and finally at relapse after 2.L therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be followed with MRD assessment every 4 month and start 2.L treatment at loss of MRD negative complete response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be followed up by standard criteria and start 2.L treatment at progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early treatment of relapse with carfilzomib, dexamethasone, daratumumab</intervention_name>
    <description>Second line treatment will start at MRD reapperance</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>DKd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab</intervention_name>
    <description>Second line treatment will start at progressive disease</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>DKd</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria part one:&#xD;
&#xD;
          -  Each patient must meet all of the following inclusion criteria to be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. Patient with newly diagnosed multiple myeloma (IMWG criteria) eligible for&#xD;
                  high-dose therapy and ASCT.&#xD;
&#xD;
               2. Patient must be &gt;18 and &lt; 75 years of age at the time of signing the informed&#xD;
                  consent&#xD;
&#xD;
               3. Must have measurable disease as defined by the International Myeloma Working&#xD;
                  Group; serum monoclonal paraprotein (M-protein) level &gt; 10 g/L or light chain&#xD;
                  multiple myeloma without measurable disease in the serum; serum immunoglobulin&#xD;
                  FLC &gt; 100 mg/L and abnormal serum immunoglobulin kappa lambda FLC ratio.&#xD;
&#xD;
               4. Voluntary written informed consent&#xD;
&#xD;
               5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.&#xD;
                  ECOG 3 can be enrolled if caused by myeloma.&#xD;
&#xD;
               6. Patient must be willing and able to adhere to the study protocol visit schedule&#xD;
                  and other protocol requirements.&#xD;
&#xD;
               7. Female of childbearing potential (FCBP) must have a confirmed negative serum&#xD;
                  pregnancy test within 7 days prior to inclusion.&#xD;
&#xD;
               8. FCBP and male subject who are sexually active with FCBP must agree to use highly&#xD;
                  effective concomitant methods of contraceptive during the study and for at least&#xD;
                  28 days following the last study drug dose. Male subjects must use contraception&#xD;
                  and refrain from donating sperm for at least 28 days after the last dose of&#xD;
                  lenalidomide according to Pregnancy Prevention Plan (Appendix 4: Contraceptive&#xD;
                  Guidance and Collection of Pregnancy Information).&#xD;
&#xD;
                  Inclusion Criteria part two:&#xD;
&#xD;
          -  Each patient must meet all of the following inclusion criteria to be enrolled in the&#xD;
             study&#xD;
&#xD;
               1. Patient must be MRD negative measured by Euroflow NGF after 1.L therapy. The&#xD;
                  cutoff for inclusion into part 2 will be 100 PC per 10 mill. nucleated cells&#xD;
                  monitored in BM.&#xD;
&#xD;
               2. Has received 1.L treatment in part 1 of the study.&#xD;
&#xD;
               3. ECOG performance status score 0, 1 or 2&#xD;
&#xD;
        Exclusion Criteria part one:&#xD;
&#xD;
          1. Received more than one cycle of induction treatment for multiple myeloma.&#xD;
&#xD;
          2. Patient with ongoing or active systemic infection, active hepatitis B or C virus&#xD;
             infection or known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          3. Concurrent medical or psychiatric condition or disease that is incompatible to HDM and&#xD;
             ASCT or that will likely result in reduced study compliance and reduce ability to&#xD;
             follow study procedures, or that in the opinion of the investigator, would constitute&#xD;
             a hazard for participating in this study.&#xD;
&#xD;
          4. No active malignancy with a lower life expectancy than myeloma&#xD;
&#xD;
          5. Female patient who have a positive serum pregnancy test during the screening period.&#xD;
&#xD;
          6. Female patient who is lactating during the screening period but are not willing to&#xD;
             stop lactating prior to the first treatment cycle starts.&#xD;
&#xD;
          7. Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent.&#xD;
&#xD;
        Exclusion Criteria part two:&#xD;
&#xD;
          1. No active malignancy with a lower life expectancy than myeloma&#xD;
&#xD;
          2. Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrik Schjesvold, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Marie Rasmussen, PhD</last_name>
    <phone>+4799791064</phone>
    <email>annemra55@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Lysen, MSC</last_name>
    <phone>+4747246569</phone>
    <email>annaly@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tor-Henrik Tvedt, MD, PhD</last_name>
      <email>tor.henrik.anderson.tvedt@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital Bodø</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randi F Halstensen, MD</last_name>
      <phone>+4775534000</phone>
      <email>randi.fykse.hallstensen@nordlandssykehuset.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Ostfold</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgitte D. Eiken, MD</last_name>
      <email>birgitte.dahl.eiken@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Førde Central Hospital</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian Szatkowski, MD</last_name>
      <phone>+4757839000</phone>
      <email>damian.szatkowski@helse-forde.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet Hospital Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Rolke, MD</last_name>
      <phone>+4790610600</phone>
      <email>jurgen.rolke@sshf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levanger Hospital</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon Hjalmar Sørbø, MD</last_name>
      <phone>+4774098000</phone>
      <email>jonhjalmar.sorbo@helse-nordtrondelag.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette L. Eilertsen, MD, PhD.</last_name>
      <email>anette.loken.eilertsen@ahus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrik Schjesvold, MD, PhD</last_name>
      <email>fredrikschjesvold@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Frida Askeland, MD</last_name>
      <email>friask@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger HF</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Einar Haukås, MD, PhD</last_name>
      <email>einar.haukas@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Vik, MD, PhD</last_name>
      <email>Anders.Vik@unn.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Slørdahl, MD, PhD</last_name>
      <email>Tobias.Schmidt.Slordahl@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital of Vestfold</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Moksnes, MD</last_name>
      <email>magmok@siv.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Brudevold, MD</last_name>
      <phone>+4740622848</phone>
      <email>robert.brudevold@helse-mr.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Fredrik Hellem Schjesvold</investigator_full_name>
    <investigator_title>Head of Oslo Myeloma Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

